(Mesa, AZ, February 25, 2013) Professor
Virgil Stenberg, Ph.D., debunks the cortisone side effect myth and demonstrates
effectiveness of a new cortisone use method.
Only two medicines have received the
rare honor and prestige associated with the Nobel Prize: insulin and cortisone.
Medical industry has embraced insulin as
a life-sustaining medicine for lifetime diabetes control.
On the other hand, medical industry has
restricted cortisone to the minor role of resolving inflammation emergencies
because of its side effects.
Stenberg, medical director of the Helen
Foundation, noted that the medical industry restriction conflicts with
elementary medical knowledge: hormones
have no side effects, and cortisone is a hormone.
“To resolve the conflict, it became
necessary to look beyond cortisone the medicine to cortisone the hormone,”
Stenberg explained.
As a hormone, cortisone is
in the blood at all times. There is a
safe operating range of cortisone within the blood like there is a safe operating
range of oil within an automobile engine.
If this safe operating range is exceeded, Cushing’s syndrome
appears. When the cortisone
concentration is lower than the safe operating range, Addison’s disease
threatens.
The relationship between
arthritis inflammation and hormone cortisone within the body has been
inadequately defined.
Normally, inflammation with
its pain, swelling and redness is caused by an injury. The natural role of new inflammation is to
prevent infection. After the danger of infection
is passed, inflammation is terminated, and the injury heals.
Stenberg discovered
inflammation is terminated by an on-demand, short-duration, huge cortisone
pulse in the blood. As this pulse
weakens, new inflammation lasts too long and evolves into old
inflammation.
To bring his wife Helen’s
severe, refractory arthritis under control, Stenberg designed replacement
cortisone tablet use to timely restore the pulse to its working size. Using his design, Helen lost all pain and swelling
in the first weeks and has remained as such for decades without cortisone side
effects.
In a double-blind clinical
trial on rheumatoid arthritis patients using the Stenberg treatment design
(microdose therapy meaning a small amount of cortisone as needed), the results
proved superior to standard treatments and with no significant side
effects. Hamdy Kh Koryem of the
University of Alexandra (Egypt) repeated the Stenberg double-blind clinical
trial with near identical results. In a
subsequent open, multi-clinic, study on 244 rheumatoid arthritis patients, the
double-blind clinical trial results were again confirmed.
Stenberg adds, “Old
inflammation has many names: rheumatoid arthritis when in the joints, bursitis
in the bursa, myocytis in the muscles, pancreatitis in the pancreas, carditis
in the heart, and so forth. One
treatment that perfectly controls old inflammation should control all. Thus far, the Helen Foundation has applied
microdose therapy to 26 diseases and disorders of inflammation for 1,890 patients
all with superior results and no significant side effects.”
Stenberg states “By making the conclusion ‘cortisone has side effects’, a great
error in medicine has been made. No
other error in medicine has caused more pain and suffering. Cortisone ‘side
effects’ are merely induced Cushing’s syndrome symptoms caused by over
administration of cortisone. Over
administration of cortisone was due to a lack of understanding of how the body
normally uses cortisone to terminate inflammation.”
Dr. Stenberg is the author of “Arthritis:
The Simple Solution” and “Fibromyalgia Solved” and has been
Editor of Proceedings of the North
Dakota Academy of Sciences
President, North Dakota Academy of
Sciences
President, Red River Valley Chapter,
American Chemical Society
President of the Board, Listen and Drop
In Center, for the mentally challenged
Board member, Interscience World
Conference on Inflammation, Geneva
Lecturer in Australia, Canada, France,
India, Japan, Mexico, and Switzerland.
Dr. Stenberg has published medical
articles on the
cortisone pulse theory:
Stenberg, V.I. et al. 1990. Negative endocrine control system
for inflammation in rats. Agents Actions 29: 189-195.
superior efficacy on a
demonstration disease of inflammation:
Stenberg, V.I. et al. 1992.
Endocrine control of inflammation: rheumatoid arthritis double-blind, crossover
clinical trial. Int J Clin Pharmacol Res 12: 11-18.
